Korea Investment CORP Reduces Stake in Amgen Inc. $AMGN

Korea Investment CORP lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 31.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 269,926 shares of the medical research company’s stock after selling 126,006 shares during the quarter. Korea Investment CORP’s holdings in Amgen were worth $97,746,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Norges Bank bought a new position in Amgen in the fourth quarter worth approximately $2,164,162,000. Capital World Investors grew its position in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. BlackRock Inc. increased its stake in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. State Street Corp raised its holdings in Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Finally, Geode Capital Management LLC lifted its position in Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 in the last 90 days. Company insiders own 0.85% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. BMO Capital Markets boosted their price objective on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Mizuho increased their target price on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday. Truist Financial lifted their target price on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Canaccord Genuity Group increased their price objective on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $380.43.

Amgen Stock Up 1.3%

Shares of AMGN opened at $439.33 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock has a market capitalization of $237.51 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 3.13 and a beta of 0.41. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $443.20. The business’s 50 day simple moving average is $379.03 and its 200-day simple moving average is $361.95.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.92 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.